Xermelo First Oral Treatment for Carcinoid Syndrome Diarrhea in Patients with Metastatic NETs
FDA Approvals, News & UpdatesNewsworthy
In February 2017, the FDA approved the oral drug Xermelo (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea, in combination with a somatostatin analog (SSA), in adults with metastatic neuroendocrine tumors (NETs) whose condition is inadequately controlled by SSA therapy. Xermelo is the first oral therapy available for patients with carcinoid syndrome diarrhea in patients with NETs.
Lexicon Announces the Launch of
NewsworthyWeb Exclusives
The new site is aimed at providing education for people with carcinoid syndrome, caregivers, and medical providers.
Common Vaccine Offers Hope Against Aggressive Brain Tumors
The median survival rate for patients with glioblastoma, an aggressive type of brain tumor, is approximately 14 months. Approximately 17% of all brain tumors are glioblastomas.
What's New in Multiple Myeloma Therapy?
FDA Approvals, News & UpdatesMultiple MyelomaNewsworthy
In the first 3 months of 2015, new developments in myeloma drugs could have important implications for the survival and quality of life of patients with multiple myeloma.
Whether a child is fighting to refuse treatment or a terminally ill adult desperately wants to try an experimental drug, patients with cancer throughout the country are attempting to break barriers that keep them from making personal choices about their treatment.
Page 6 of 6
Results 51 - 55 of 55

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.